Outcomes of Hypertensive Kidney Donors Using Current and Past Hypertension Definitions

Brenner, 1988, Glomeruli and blood pressure. Less of one, more the other?, Am J Hypertens, 1, 335, 10.1093/ajh/1.4.335

Kanzaki, 2015, Factors associated with a vicious cycle involving a low nephron number, hypertension and chronic kidney disease, Hypertens Res, 38, 633, 10.1038/hr.2015.67

2018

Anjum, 2016, Patterns of end-stage renal disease caused by diabetes, hypertension, and glomerulonephritis in live kidney donors, Am J Transplant, 16, 3540, 10.1111/ajt.13917

Holscher, 2019, Self-reported incident hypertension and long-term kidney function in living kidney donors compared with healthy nondonors, Clin J Am Soc Nephrol, 14, 1493, 10.2215/CJN.04020419

Al Ammary, 2019, Risk of ESKD in older live kidney donors with hypertension, Clin J Am Soc Nephrol, 14, 1048, 10.2215/CJN.14031118

Mandelbrot, 2007, The medical evaluation of living kidney donors: a survey of US transplant centers, Am J Transplant, 7, 2333, 10.1111/j.1600-6143.2007.01932.x

Schlessinger, 1994, Clinical documentation of end-stage renal disease due to hypertension, Am J Kidney Dis, 23, 655, 10.1016/S0272-6386(12)70275-5

Caetano, 2001, Hypertensive nephrosclerosis as a relevant cause of chronic renal failure, Hypertension, 38, 171, 10.1161/01.HYP.38.2.171

Wright, 2015, A randomized trial of intensive versus standard blood-pressure control, N Engl J Med, 373, 2103, 10.1056/NEJMoa1511939

Whelton, 2017, J Am Coll Cardiol, 71, e127, 10.1016/j.jacc.2017.11.006

Taler, 2013, Demographic, metabolic, and blood pressure characteristics of living kidney donors spanning five decades, Am J Transplant, 13, 390, 10.1111/j.1600-6143.2012.04321.x

Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006

Hastie, 2015

2019

Harrell, 1982, Evaluating the yield of medical tests, JAMA, 247, 2543, 10.1001/jama.1982.03320430047030

Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144

Hsu, 2005, Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease, Arch Intern Med, 165, 923, 10.1001/archinte.165.8.923

1976, The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease, JAMA, 235, 825, 10.1001/jama.1976.03260340031016

Perry, 1977, Treatment of mild hypertension. Preliminary results of a two-year feasibility trial, Circ Res, 40, I180

Iseki, 1996, Risk of developing end-stage renal disease in a cohort of mass screening, Kidney Int, 49, 800, 10.1038/ki.1996.111

Grams, 2016, Kidney-failure risk projection for the living kidney-donor candidate, N Engl J Med, 374, 2094, 10.1056/NEJMoa1510491

Freedman, 2012, Target organ damage in African American hypertension: role of APOL1, Curr Hypertens Rep, 14, 21, 10.1007/s11906-011-0237-4

Lentine, 2010, Racial variation in medical outcomes among living kidney donors, N Engl J Med, 363, 724, 10.1056/NEJMoa1000950

Sanchez, 2018, Hypertension after kidney donation: incidence, predictors and correlates, AM J Transplant, 18, 2534, 10.1111/ajt.14713

Wolf-Maier, 2003, Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States, JAMA, 289, 2363, 10.1001/jama.289.18.2363